Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2017 Financial and Operating Results

GlobeNewswire March 28, 2018

Aeterna Zentaris Inc. to Host Earnings Call

Accesswire March 28, 2018

Earnings Scheduled For March 27, 2018

Benzinga.com  March 27, 2018

Aeterna Zentaris to Announce Fourth Quarter and Year End 2017 Financial and Operating Results on March 28th, 2018

GlobeNewswire March 21, 2018

Aeterna Zentaris Appoints James Clavijo as Chief Financial Officer

GlobeNewswire March 5, 2018

Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit

GlobeNewswire March 5, 2018

Mid-Afternoon Market Update: NeuroMetrix Climbs Following Announcement Of Collaboration With GlaxoSmithKline; Aerohive Networks Shares Drop

Benzinga.com  January 17, 2018

38 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  January 17, 2018

30 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  January 17, 2018

Aeterna Zentaris Enters into Licensing and Assignment Agreement with Strongbridge for Macrilen™ (macimorelin) in the U.S. and Canada

GlobeNewswire January 17, 2018

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

GlobeNewswire January 17, 2018

44 Biggest Movers From Friday

Benzinga.com  December 26, 2017

Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore

GlobeNewswire December 22, 2017

36 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  December 22, 2017

38 Biggest Movers From Yesterday

Benzinga.com  December 22, 2017

Mid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide

Benzinga.com  December 21, 2017

36 Stocks Moving In Thursday's Mid-Day Session

Benzinga.com  December 21, 2017

Mid-Day Market Update: Dow Surges Over 100 Points; PG&E Shares Plunge

Benzinga.com  December 21, 2017

IIROC Trade Resumption - AEZS; BNE

Canada NewsWire December 21, 2017

IIROC Trade Resumption - Aeterna Zentaris Inc.

Newsfile December 21, 2017